- Priced 6 million shares of common stock at $15.00 per share.
- Jefferies LLC, Leerink Partners LLC, and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the offering. Robert W. Baird & Co. Incorporated is acting as co-lead manager for the offering.
Description
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company intends to discover, develop and commercialize therapeutics either on its own or in collaboration with pharmaceutical partners. The Company has partnered two of its oncology development programs with the global pharmaceutical company Kyowa Hakko Kirin Co., Ltd. The Company is developing DCR-PH1 for the treatment of the rare and serious inherited disorder PH1 by targeting the liver metabolic enzyme glycolate oxidase.
Address
Building 1 Suite 120, 480 Arsenal Street
WATERTOWN, MA 02472
United States
WATERTOWN, MA 02472
United States
Website :
http://www.dicerna.comKey stats and ratios
| Q3 (Sep '13) | 2012 | |
| Net profit margin | - | -144.28% |
| Operating margin | - | -131.86% |
| EBITD margin | - | -124.01% |
| Return on average assets | -56.86% | -58.12% |
| Return on average equity | - | - |
| Employees | 24 |
No comments:
Post a Comment